CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8,101 enrolled
Drug / intervention
Rivaroxaban (Xarelto, BAY59-7939) +3 moredrug
Likely dose
Rivaroxaban (Xarelto, BAY59-7939) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00571649
NCT00571649Phase 3Completed
CompareCT.gov

Multicenter, Randomized, Parallel-group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients Comparing Rivaroxaban With Enoxaparin. The MAGELLAN Study

Bayer·interventional·Posted Dec 12, 2007·Updated Sep 15, 2016

In Brief

A Phase 3 clinical trial evaluating Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, and 2 other interventions for Venous Thromboembolism. Completed, enrolled 8,101 participants across 676 sites in 53 countries.

Detailed Summary

This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Pakistan, Peru, Poland, Portugal, Romania, Russia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
CollaboratorsJohnson & Johnson Pharmaceutical Research & Development, L.L.C.

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2010
Study CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.6 years ago

Interventions

Rivaroxaban (Xarelto, BAY59-7939)drug

Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days

Enoxaparindrug

Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days

Rivaroxaban placebodrug

Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days

Enoxaparin placebodrug

Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days